Prevalence of unrecognized abnormal glucose tolerance in patients attending a hospital hypertension clinic

American Journal of Hypertension

Volumn 17, Issue 6, 2004, Pages 483-488

  Salmasi, Abdul Majeed ^a   Alimo, Audrey ^a   Dancy, Mark ^a  

^a CENTRAL MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

diabetes mellitus; Glucose tolerance; hypertension; impaired fasting glucose; impaired glucose tolerance

Indexed keywords

CHOLESTEROL; POTASSIUM; SODIUM;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BLOOD PRESSURE MONITORING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DEMOGRAPHY; ETHNOLOGY; FEMALE; GLUCOSE INTOLERANCE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; ORAL GLUCOSE TOLERANCE TEST; OUTPATIENT DEPARTMENT; POTASSIUM BLOOD LEVEL; PREVALENCE; PRIORITY JOURNAL; SMOKING; SODIUM BLOOD LEVEL;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE MONITORING, AMBULATORY; DIABETES MELLITUS; FEMALE; GLUCOSE TOLERANCE TEST; GREAT BRITAIN; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OUTPATIENT CLINICS, HOSPITAL; PREVALENCE; STATISTICS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 2642533429     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2004.01.011     Document Type: Article

References (33)

1. Williams D.R., Wareham N.J., Brown D.C., et al. Undiagnosed glucose intolerance in the community the Isle of Ely Diabetes project. Diabet Med. 12:1995;30-35
2. Garancini MP, Calori G, Ruotolo G, Manara E, Izzo A, Ebbli E, Bozzetti AM, Boari L, Lazzari P, Gallus G: Prevalence of NIDDM and impaired glucose tolerance in Italy: an OGTT-based population study. Diabetologia 1995;38:306-313
3. Simmons D., Williams D.R., Powell M.J. Prevalence of DM in a predominantly Asian community preliminary findings of the Coventry DM study. Br Med J. 298:1989;18-21
4. Kannel W.B. Blood pressure as a cardiovascular risk factor prevention and treatment. JAMA. 275:1996;1571-1576
5. Kannel W.B. Potency of vascular risk factors as the basis for antihypertensive therapy. Eur Heart J. 13:(Suppl G):1992;34-42
6. World Health Organisation Expert Committee on Diabetes Mellitus. Second Report. WHO Technical Report Series no. 646. 1980;World Health Organization, Geneva
7. Tai M.M. A mathematical model for the determination of total area under glucose tolerance and other metabolic curves. Diabetes Care. 17:1994;152-154
8. Davies M.J., Ammari F., Sherriff C., Burden M.L., Gujral J., Burden A.C. Screening for type 2 DM mellitus in the UK Indo-Asian population. Diabet Med. 16:1999;131-137
9. Friderichsen B., Maunsbach M. Glycosuric tests should not be employed in population screening for NIDDM. J Public Health Med. 19:1997;55-60
10. Nakagami T., Qiao Q., Tuomilehto J., et al. The fasting plasma glucose cut-point predicting a diabetic 2-h OGTT glucose level depends on the phenotype. Diabet Res Clin Pract. 55:2002;35-43
11. Barree-Connor E., Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men the Rancho Bernardo study. Diabetes Care. 21:1998;1236-1239
12. Shaw J.E., de Courten M., Boyko E.J., Zimmet P.Z. Impact of new diagnostic criteria for DM on different populations. Diabetes Care. 22:1999;762-766
13. DECODE study group, on behalf of the European Diabetes Epidemiology Group. Is fasting glucose sufficient to define DM? Epidemiological data from 20 European studies. Diabetologia. 22:1999;647-654
14. Vaccaro O., Ruffa G., Imperatore G., Iovino V., Rivellese A.A., Ricardi G. Risk of DM in the new diagnostic category of impaired fasting glucose. Diabetes Care. 22:1999;1490-1493
15. Shaw J.E., Zimmet P.Z., de Couten M., et al. Impaired fasting glucose or impaired glucose tolerance? Diabetes Care. 22:1999;399-402
16. Weinberger M.H., Fineberg N.S., Fineberg E.F. The influence of BP and carbohydrate tolerance on vascular compliance in humans. Am J Hypertension. 15:2002;678-682
17. Ruige J.B., Assendelft W.J.J., Dekker J.M., Kostense P.J., Heine R.J., Bouter L.M. Insulin and risk of cardiovascular disease, a meta-analysis. Circulation. 97:1998;996-1001
18. Pyorala M., Miettinen H., Halonen P., Laakso M., Pyorala K. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men the 22-year follow-up results of the Helsinki Policemen Study. Circulation. 98:1998;398-404
19. Pyorala M., Miettinen H., Halonen P., Laakso M., Pyorala K. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men, the 22-year follow-up results of the Helsinki Policemen Study. Arterioscler Thromb Vasc Biol. 20:2000;538-544
20. Lempiainen P., Mykkanen L., Pyorala K., Laakso M., Kuuissto J. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation. 100:1999;123-128
21. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 DM UKPDS 38. Br Med J. 317:1998;703-713
22. Sowers J.R., Epstein M. Diabetes mellitus and associated hypertension, vascular disease and nephropathy. Hypertension. 26:1995;869-879
23. Unwin N., Shaw J., Zimmet P., Alberti K.G. Impaired glucose tolerance and impaired fasting glycaemia the current status on definition and intervention. Diabet Med. 19:2002;708-723
24. Dinneen S.F., Maldonado D. III, Leibson C.L., Klee G.G., Li H., Melton L.J. III, Rizza R.A. Effects of changing diagnostic criteria on the risk of developing DM. Diabetes Care. 21:1998;1408-1413
25. Charles M.A., Fontbonne A., Thibult N., Warnet J.M., Rosselin G.E., Eschwege E. Risk factors for NIDDM in white population Paris Prospective Study. Diabetes. 40:1991;796-799
26. 1c to improve efficacy of the American Diabetes Association fasting plasma glucose criterion in screening for new type 2 DM in American Indians the Strong Heart Study. Diabetes Care. 25:2002;1365-1370
27. Tominaga M., Eguchi H., Manaka H., Igarashi K., Kato T., Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Fungata Diabetes Study. Diabetes Care. 22:1999;920-924
28. Bonora E. Postprandial peaks as a risk factor for cardiovascular disease epidemiological perspectives. Int J Clin Pract. 129:2002;5-11
29. Meigs J.B., Larson M.G., D'Agostino R.B., Levy D., Clouse M.E., Nathan D.M., Wilson P.W.F., O'Donnell C.J. Coronary artery calcification in type 2 DM and insulin resistance. The Framingham Offspring Study. Diabetes Care. 25:2002;1313-1319
30. Bur A., Herkner H., Woisetschlger C., Vlcek M., Derhaschnig U., Hirschi M.M. Is fasting blood glucose a reliable parameter for screening for DM in hypertension. Am J Hypertens. 16:2003;297-301
31. Giles R.D., Yusuf S., Bourasa M.G., Yi Q., Bosch J., Lonn E.M., Kouz S., Grover J. HOPE Investigators. Effects of ramipril on coronary events in high-risk persons. Results of the Heart Outcome Prevention Evaluation Study. Circulation. 104:2001;522-526
32. Arnold J.M.O., Yusuf S., Young J., Mathew J., Johnston D., Avezum A., Lonn E., Pogue J., Bosch J. HOPE Investigators. Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation. 107:2003;1284-1290
33. Bosch J., Yusuf S., Pogue J., Sleight P., Lonn E., Rangoonwala B., Davies R., Ostergren J., Probstfield J. HOPE Investigators. Br Med J. 324:2002;699-702